medigraphic.com
ISSN 1561-2937 (Print)

2017, Number 2

<< Back Next >>

Rev Cubana Cardiol Cir Cardiovasc 2017; 23 (2)

Restrictive cardiomyopathy secondary to Hypereosinophilic Syndrome

Jerez CAM, Escobar OY, Heres ÁF, González GOR, González TA, de Araujo CMJ

Language: Spanish
References: 12
Page:
PDF size: 526.13 Kb.


ABSTRACT

Restrictive cardiomyopathy secondary to Hyperosinophilic Syndrome (SHE) is rare; it constitutes a group of diseases characterized by an overproduction of eosinophils, with secondary damage of multiple organs caused by eosinophilic infiltration and the release of mediators. Divided into three phases, eosinophilic myocarditis is divided into three phases and it is the major cause of morbidity and mortality and restrictive cardiomyopathy is the final phase of the condition, which it corresponds to the patient presented.


REFERENCES

  1. Hardy WR, Anderson RE. The hypereosinophilic syndrome. Annals Intern Med 1968; 68:1220-1229.

  2. Chusid MJ, Dale DC, West BC, Wolf SM. The hypereosinophilic syndrome:analysis of fourteen cases with review of the literature. Medicine (Baltimore) 1975; 54:1-27.

  3. Loeffler JH. The Loeffler hypereosinophilic syndrome. Medicine 1936; 67:4-31.

  4. Von Gunten S, Vogel M, Schaub A, et al. Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies. J Allergy Clin Immunol 2017; 119:1005-1011. [Epub ahead of print].

  5. Halaburda K, Prejzner W, Szatkowski D, et al. Allogeneic bone marrow transplantation for hypereosinophilic syndrome: long-term follow-up with the eradication of FIP1L1-PDGFRA fusion transcript. Bone Marrow Transplant 2016; 38:319-320.

  6. Sefcick A, Sowter D, DasGupta E, Russell NH, Byrne JL. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome. Br J Haematol 2014; 124: 558-9.

  7. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesylate. Lancet 2015; 359: 1577-8.

  8. Moore PM, Harley JB, Fauci AS. Neurologic dysfunction in the idiopathic hypereosinophilic syndrome. Ann Intern Med 2015; 102: 109-14.

  9. Moraes R G. Contribucao para o studo do Strongyloides stercoralis e da strongyloidosis no Brasil. Rev Servi Esp Salude Public 2014; 1: 507-624.

  10. Berensztein CS, Roisinblit J, Torino A, Suárez LD. Miocardiopatías restrictivas. Buenos Aires, Argentina. Edimed. 2017.

  11. Roufosse F. Management of Hypereosinophilic Syndromes. Immunol Allergy Clin N Am 2015; 35: 561-575.

  12. Tabata R, Tabata Ch, Katashima Y, Yasumizu R. Effect of cyclosporine on lymphocytic variant hypereosinophilic syndrome. Int Immunol Pharmacol 2013; 16: 488-491.




2020     |     www.medigraphic.com